Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MLTX NASDAQ:OLMA NASDAQ:QURE NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLTXMoonLake Immunotherapeutics$17.86-5.2%$17.47$5.95▼$62.75$1.28B1.011.69 million shs426,934 shsOLMAOlema Pharmaceuticals$13.54-8.9%$16.20$3.89▼$36.26$1.19B2.051.42 million shs463,422 shsQUREuniQure$27.29-1.3%$16.94$8.73▼$71.50$1.72B0.872.85 million shs640,861 shsRZLTRezolute$3.30+3.9%$3.13$1.07▼$11.46$316.29M0.662.79 million shs589,770 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLTXMoonLake Immunotherapeutics+10.43%+12.61%+4.90%+20.61%-51.03%OLMAOlema Pharmaceuticals-0.27%+3.77%-7.70%-36.41%+223.04%QUREuniQure-0.07%+44.49%+79.71%+11.86%+116.28%RZLTRezolute-1.25%-3.94%-12.91%+3.26%-14.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLTXMoonLake Immunotherapeutics$17.86-5.2%$17.47$5.95▼$62.75$1.28B1.011.69 million shs426,934 shsOLMAOlema Pharmaceuticals$13.54-8.9%$16.20$3.89▼$36.26$1.19B2.051.42 million shs463,422 shsQUREuniQure$27.29-1.3%$16.94$8.73▼$71.50$1.72B0.872.85 million shs640,861 shsRZLTRezolute$3.30+3.9%$3.13$1.07▼$11.46$316.29M0.662.79 million shs589,770 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLTXMoonLake Immunotherapeutics+10.43%+12.61%+4.90%+20.61%-51.03%OLMAOlema Pharmaceuticals-0.27%+3.77%-7.70%-36.41%+223.04%QUREuniQure-0.07%+44.49%+79.71%+11.86%+116.28%RZLTRezolute-1.25%-3.94%-12.91%+3.26%-14.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLTXMoonLake Immunotherapeutics 2.38Hold$23.8533.52% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.40228.04% UpsideQUREuniQure 2.53Moderate Buy$42.8356.97% UpsideRZLTRezolute 2.45Hold$8.00142.79% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, OLMA, QURE, and MLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.005/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $50.005/5/2026QUREuniQure Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.004/30/2026QUREuniQure Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $37.004/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RZLTRezolute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$9.00 ➝ $10.003/30/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/27/2026OLMAOlema Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/25/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.00 ➝ $5.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/AQUREuniQure$16.10M106.90N/AN/A$3.19 per share8.55RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLTXMoonLake Immunotherapeutics-$227.32M-$3.52N/AN/AN/AN/A-66.56%-50.23%N/AOLMAOlema Pharmaceuticals-$162.45M-$1.86N/AN/AN/AN/A-42.95%-38.78%5/12/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%N/ARZLTRezolute-$74.41M-$0.93N/AN/AN/AN/A-64.81%-59.37%5/12/2026 (Estimated)Latest RZLT, OLMA, QURE, and MLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/12/2026Q3 2026RZLTRezolute-$0.1686N/AN/AN/AN/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A3/3/2026Q4 2025QUREuniQure-$0.93-$0.56+$0.37-$0.56$4.84 million$5.57 million2/25/2026Q4 2025MLTXMoonLake Immunotherapeutics-$0.92-$0.92N/A-$0.92N/AN/A2/12/2026Q2 2026RZLTRezolute-$0.16-$0.22-$0.06-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLTXMoonLake Immunotherapeutics0.249.279.27OLMAOlema Pharmaceuticals0.019.959.95QUREuniQure0.3310.4010.40RZLTRezoluteN/A14.1814.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLTXMoonLake Immunotherapeutics93.85%OLMAOlema Pharmaceuticals91.78%QUREuniQure78.83%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipMLTXMoonLake Immunotherapeutics12.05%OLMAOlema Pharmaceuticals16.36%QUREuniQure4.79%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLTXMoonLake Immunotherapeutics271.73 million63.09 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableQUREuniQure50063.07 million60.05 millionOptionableRZLTRezolute4095.70 million81.55 millionOptionableRZLT, OLMA, QURE, and MLTX HeadlinesRecent News About These CompaniesRezolute to Participate in Upcoming Investor ConferencesMay 11 at 7:00 AM | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Receives Consensus Rating of "Hold" from AnalystsMay 11 at 4:34 AM | marketbeat.comRezolute (RZLT) Expected to Announce Quarterly Earnings on TuesdayMay 10 at 3:55 AM | americanbankingnews.comRezolute (RZLT) to Release Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comRezolute, Inc. Investigated by the Portnoy Law FirmApril 24, 2026 | globenewswire.comRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingApril 21, 2026 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in MarchApril 16, 2026 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Hold" by BrokeragesApril 16, 2026 | marketbeat.comRezolute: Sell Rating Despite FDA Feedback From Type B Meeting For ErsodetugMarch 30, 2026 | seekingalpha.comWedbush upgrades Rezolute (RZLT)March 26, 2026 | msn.comRezolute Stock Gains After FDA Meeting on Ersodetug Program UpdateMarch 25, 2026 | zacks.comFDA Review Puts Rezolute's Genetic Disorder Drug Path In QuestionMarch 24, 2026 | benzinga.comRezolute gains after positive FDA meeting over lead assetMarch 24, 2026 | msn.comRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingMarch 24, 2026 | globenewswire.comRZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into RezoluteMarch 6, 2026 | businesswire.comINVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)March 5, 2026 | prnewswire.comRezolute to Participate in the Citizens Life Sciences ConferenceMarch 4, 2026 | globenewswire.comRZLT SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteMarch 3, 2026 | globenewswire.comRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 28, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT, OLMA, QURE, and MLTX Company DescriptionsMoonLake Immunotherapeutics NASDAQ:MLTX$17.86 -0.98 (-5.20%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Olema Pharmaceuticals NASDAQ:OLMA$13.54 -1.33 (-8.92%) As of 11:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.uniQure NASDAQ:QURE$27.29 -0.35 (-1.27%) As of 11:56 AM Eastern This is a fair market value price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Rezolute NASDAQ:RZLT$3.30 +0.13 (+3.94%) As of 11:56 AM Eastern This is a fair market value price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
